Edition:
United States

Protagonist Therapeutics Inc (PTGX.OQ)

PTGX.OQ on NASDAQ Stock Exchange Global Market

16.89USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$16.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
47,480
52-wk High
$23.36
52-wk Low
$8.00

Select another date:

Thu, Jan 4 2018

BRIEF-Protagonist Therapeutics Granted Two New US Patents For Peptide Drug Candidates PTG-100 And PTG-300

* PROTAGONIST THERAPEUTICS GRANTED TWO NEW US PATENTS FOR PEPTIDE DRUG CANDIDATES PTG-100 AND PTG-300 Source text for Eikon: Further company coverage:

BRIEF-Protagonist Therapeutics Appoints Sarah Noonberg To Board

* PROTAGONIST THERAPEUTICS APPOINTS SARAH NOONBERG TO THE BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Protagonist Therapeutics Announces Final Phase 1 Study Results With Novel Hepcidin Mimetic, PTG-300

* PROTAGONIST THERAPEUTICS ANNOUNCES FINAL PHASE 1 STUDY RESULTS WITH NOVEL HEPCIDIN MIMETIC, PTG-300

BRIEF-Protagonist Therapeutics initiates phase 1 trial of oral peptide PTG-200

* Protagonist Therapeutics initiates phase 1 trial of oral peptide IL-23 receptor antagonist, PTG-200

BRIEF-Protagonist Therapeutics Q3 ‍net loss per share $0.29​

* Protagonist Therapeutics reports third quarter 2017 financial results and provides corporate update

BRIEF-Protagonist Therapeutics prices offering of 3.53 mln common shares at $17 per share

* Says public offering of 3.53 million common shares priced at $17.00 per share Source text for Eikon: Further company coverage:

BRIEF-Protagonist Therapeutics announces proposed public offering of common stock

* Protagonist Therapeutics announces proposed public offering of common stock

BRIEF-Protagonist Therapeutics Inc files for mixed shelf of up to $200 million - SEC filing ‍​

* Protagonist Therapeutics Inc files for mixed shelf of up to $200 million - SEC filing ‍​ Source text: (http://bit.ly/2xDBQBh) Further company coverage:

BRIEF-Protagonist Therapeutics announces closing of Janssen license

* Protagonist Therapeutics announces closing of Janssen license and collaboration agreement for PTG-200 and receipt of $50 million payment

Select another date: